C
ancer prediction nomograms provide advanced practitioners (APs) with tools to assess a patient's overall risk for development of a specific cancer. Alternatively, after a cancer diagnosis has been made, nomograms represent a standardized means to provide a statistical estimate of prognosis, particularly in individuals with characteristics of high-risk disease. According to the National Cancer Institute (NCI), these prediction models are a means to "facilitate the design and planning of clinical cancer trials, foster the development of benefit-risk indices, and enable estimates of the population burden and cost of cancer" (NCI, 2014a) .
PATIENT EDUCATION AND APPROPRIATE USE OF NOMOGRAMS
As APs in oncology, we frequently educate patients on the risks of current or recurrent disease status. Incorporating these cancer prediction nomograms, or "prediction tools," into patient education may also provide supportive statistical evidence for patients to make knowledgeable decisions regarding treatment. It is important to note that cancer prediction nomograms are supportive tools for use in both treatment planning and as a part of a comprehensive education on best evidence for patients.
Predictive nomograms are based on the statistical probability of disease risk on the basis of identified characteristics and are not intended for use as a substitute for physician diagnosis. Patients should be cautioned that nomograms should not be used as the sole means to determine risk for development of disease or to recommend treatment for a specific type of cancer but rather for use as a tool in the comprehensive care management of any patient (Memorial Sloan Kettering Cancer Center [MSKCC], 2014) .
The list below is a compilation of selected risk calculators associated with several common cancers. They are based on statistical modeling from large patient databases and represent current best evidence for disease-specific risk of cancer development and recurrence or for prognosis. The BOADICEA (Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm) model is a risk assessment tool developed to estimate the probability of developing breast or ovarian cancer associated with mutations in BRCA1 and BRCA2. This tool is not easily accessed; it requires enrollment in the site. But because this prediction nomogram is intended to estimate the possibility of cancer susceptibility gene mutation specific to families or individuals, it may be particularly useful for screening those considering genetic testing (NCI, 2014b).
BREAST AND OVARIAN CANCERS

PROSTATE CANCER Prostate Cancer Nomogram: Pretreatment (MSKCC) http://nomograms.mskcc.org/Prostate/PreTreatment.aspx
The MSKCC risk assessment for prostate cancer recurrence (pretreatment) is the most commonly used nomogram for patients initially diagnosed with prostate cancer. This nomogram helps patients to understand the statistical probability, in percentages, of having disease that will recur based on the treatment they elect to undergo at the time of diagnosis. It is based on the clinical information obtained at the time of diagnosis, such as Gleason score, prostatespecific antigen (PSA) value, number of positive and negative biopsy cores, and stage of disease on examination.
Although patients can input this information themselves, it is most valuable when discussed with a clinician who can assist with the interpretation of the results. In contrast to the Gail model, this particular nomogram provides more detail than a statistical percentage: It provides percentage risk for a variety of factors, including involvement of extracapsular areas, seminal vesicles, and lymph nodes. Advanced practitioners can use these percentages to compare treatment options with patients. Interpreting the nomogram results and discussing the implications in great detail may be beneficial in assisting patients with their treatment decisions. The kidney cancer prediction nomograms from Fox Chase are comprehensive and pathway specific (Fox Chase Cancer Center, 2014 These two tools from Fox Chase provide a statistical estimate of the following:
1. Likelihood of a complete response to platinum-based chemotherapy, based on the histology, site of disease, extent of disease, and baseline markers at diagnosis for patients with testicular cancer; 2. Prognosis for patients who progress after platinum-based chemotherapy; specific to individuals with a nonseminomatous germ cell pathology and is calculated based on time to relapse, whether the response to chemotherapy was complete or incomplete, and markers present at the time of relapse.
FURTHER RESOURCES
For detailed information on the current nomograms available for a variety of diseases, the Epidemiology and Genomics Research Program at the NCI maintains a comprehensive listing of those in current use or under development (NCI, 2014c) . This site is an up-to-date resource for APs; it contains a comprehensive listing of peer-reviewed risk-prediction models that can be beneficial teaching tools for current oncology practice. l
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